ContraVir Pharmaceuticals (CTRV) Hits New 12-Month Low at $0.46

Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) reached a new 52-week low during trading on Thursday . The company traded as low as $0.46 and last traded at $0.52, with a volume of 3050 shares. The stock had previously closed at $0.51.

Separately, Maxim Group upgraded ContraVir Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 10th.

ContraVir Pharmaceuticals (NASDAQ:CTRV) last issued its quarterly earnings results on Tuesday, August 14th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter.

A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Barclays PLC boosted its stake in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 81.7% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 534,032 shares of the biopharmaceutical company’s stock after acquiring an additional 240,052 shares during the period. Barclays PLC owned 0.63% of ContraVir Pharmaceuticals worth $125,000 as of its most recent SEC filing. 4.79% of the stock is currently owned by hedge funds and other institutional investors.

About ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection.

Read More: Do You Need a Fiduciary?

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply